ENCL
Enclomiphene
Not a peptide. The trans (E) stereoisomer of clomifene, a triphenylethylene. Clomifene as normally supplied is a mixture of two stereoisomers with opposing activity at the estrogen receptor; enclomiphene is the antagonist isomer isolated from that mixture.
Enclomiphene has 19 registered human studies on ClinicalTrials.gov, reaching phase 3, covering 2,189 planned or enrolled participants across the 19 studies that published a figure. No FDA-approved product contains Enclomiphene. 19 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Enclomiphene; the registry search is fuzzy, so every match is re-checked. None of this says whether Enclomiphene works or is safe.
FDA status
Research only
Human studies
19
Furthest phase
Phase 3
Papers, 10 yr
19
Readership
66
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
19
Registered human studies
Phase 3
Furthest phase reached
2,189
Planned or enrolled participants, across 19 studies that published a figure
None
No FDA-approved product contains it
258 loose registry matches were checked and 19 confirmed — 239 named something else and were discarded. We count a study only when Enclomiphene is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Enclomiphene is, and what it has been studied for
Enclomiphene is classified by ChEMBL as a small molecule, and appears in trial registrations under ICI-46476 and RMI 16,289. Its FDA substance identifier is R6D2UI4FLS.
Across 19 registered trials, it has been studied in Secondary Hypogonadism, Infertility, Drug-drug Interaction and Effect of Treatment on Bone Mineral Density. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Repros Therapeutics Inc. and Baylor College of Medicine. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Enclomiphene reached Phase 3 across 19 registered trials.
No FDA-approved product contains Enclomiphene. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Enclomiphene?
Papers published each year that name Enclomiphene in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 3 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 2 | 0 | Yes |
| 2020 | 1 | 0 | Yes |
| 2021 | 1 | 0 | Yes |
| 2022 | 1 | 0 | Yes |
| 2023 | 3 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 5 | 0 | Yes |
| 2026 | 3 | 0 | No |
19 papers between 2017 and 2026. A paper counts when “Enclomiphene” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Enclomiphene
19 indexed papers name Enclomiphene in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Safety and efficacy of enclomiphene and clomiphene for hypogonadal men
- Enclomiphene citrate for the treatment of secondary male hypogonadism
- Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men
- Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
- Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism
- Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis
- British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism
- Clomiphene Citrate and Enclomiphene Hydrochloride Exposure Is Associated With Interfrontal Suture Fusion in Zebrafish
Collected 2026-08-02from PubMed, phrase-matched on “Enclomiphene” in title and abstract. Run the same search.
About Enclomiphene
Not a peptide. The trans (E) stereoisomer of clomifene, a triphenylethylene. Clomifene as normally supplied is a mixture of two stereoisomers with opposing activity at the estrogen receptor; enclomiphene is the antagonist isomer isolated from that mixture.
- Also known as
- trans-Clomiphene
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.